Nav: Home

Surgery using ultrasound energy found to treat high blood pressure

March 18, 2019

A one-off operation that targets the nerves connected to the kidney has been found to maintain reduced blood pressure in hypertension patients for at least six months, according to the results of a clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust, and supported by the National Institute for Health Research (NIHR).

The study, published in the journal Circulation and presented at the American College of Cardiology Conference in New Orleans, USA, also found that the patients treated with the procedure required fewer blood pressure medications.

If the findings are confirmed in larger and longer clinical trials, the surgery could offer hope to patients with high blood pressure who do not respond to drugs, and are at increased risk of cardiovascular diseases, including stroke and heart attack.

The international clinical trial, carried out at St Bartholomew's Hospital in the UK by the NIHR Barts Biomedical Research Centre, tested a one-hour operation called 'renal denervation', which uses ultrasound energy to disrupt the nerves between the kidneys and the brain that carry signals for controlling blood pressure.

Patients in the United States, France, Germany, the Netherlands, Belgium and the United Kingdom were randomised to receive either renal denervation or a 'sham procedure' - the surgical equivalent of a placebo.

Previous results from the study showed that renal denervation led to a significant and safe blood pressure lowering effect after two months in patients not taking antihypertensive medication.

In this second part of the study, the team investigated 140 patients to see if renal denervation remained effective in patients who had the option of restarting their blood pressure medication if required. They found that:
  • The blood pressure lowering effect of renal denervation was maintained six months after the operation, with a greater proportion of patients treated with renal denervation (58 per cent) achieving blood pressure control compared to sham (42 per cent)

  • Though the majority of patients needed the addition of medications to improve blood pressure control, more than twice as many patients were completely free of medication at 6 months in the treatment arm vs. sham arm (35.8 per cent vs 15.5 per cent).

  • Renal denervation reduced blood pressure to a greater extent than sham (an 18.1 mmHg reduction in blood pressure, compared to a 15.6 mmHg reduction) at six months

  • There were no safety concerns in either group throughout the six months.
UK Principal Investigator Professor Melvin Lobo from Queen Mary University of London and Barts Health NHS Trust said: "These results point towards an exciting future for this new technology. If long term safety and efficacy is proven in larger trials which are currently under way, we hope that renal denervation therapy could soon be offered as an alternative to many lifelong medications for hypertension."
-end-
The study was funded by ReCor Medical, Inc. which manufactures the Paradise® Renal Denervation System used in the study.

Notes to the editor
  • Research paper: 'Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial'. Prof. Michel Azizi, MD, PhD; Prof. Roland E. Schmieder, MD; Prof. Felix Mahfoud, MD; Prof. Michael A. Weber, MD; Joost Daemen, MD, PhD; Prof. Melvin D. Lobo, PhD, FRCP; Andrew SP Sharp, MD; Michael J. Bloch, MD; Jan Basile, MD; Yale Wang, MD; Manish Saxena, MBBS, MSc; Philipp Lurz, MD, PhD; Florian Rader, MD, MSc; Jeremy Sayer, MD, FRCP; Naomi DL Fisher, MD; David Fouassier, MD; Neil C. Barman, MD; Helen Reeve-Stoffer, PhD; Candace McClure, PhD; and Ajay J. Kirtane, MD, SM; on behalf of the RADIANCE-HTN Investigators. Circulation.
About Queen Mary University of London

At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable.

In 1785, Sir William Blizard established England's first medical school, The London Hospital Medical College, to improve the health of east London's inhabitants. Together with St Bartholomew's Medical College, founded by John Abernethy in 1843 to help those living in the City of London, these two historic institutions are the bedrock of Barts and The London School of Medicine and Dentistry.

Today, Barts and The London continues to uphold this commitment to pioneering medical education and research. Being firmly embedded within our east London community, and with an approach that is driven by the specific health needs of our diverse population, is what makes Barts and The London truly distinctive.

Our local community offer to us a window to the world, ensuring that our ground-breaking research in cancer, cardiovascular and inflammatory diseases, and population health not only dramatically improves the outcomes for patients in London, but also has a far-reaching global impact.

This is just one of the many ways in which Queen Mary is continuing to push the boundaries of teaching, research and clinical practice, and helping us to achieve the previously unthinkable.

About Barts Health NHS Trust

With a turnover of £1.4 billion and a workforce of around 16,000, Barts Health is the largest NHS trust in the country, and one of Britain's leading healthcare providers. The Trust's five hospitals - St Bartholomew's Hospital in the City, including the Barts Heart Centre, The Royal London Hospital in Whitechapel, Newham University Hospital in Plaistow, Whipps Cross University Hospital in Leytonstone and Mile End - deliver high quality compassionate care to the 2.5 million people of East London and beyond.

About the National Institute for Health Research

The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
  • Funds, supports and delivers high quality research that benefits the NHS, public health and social care
  • Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
  • Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
  • Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
  • Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR commissions applied health research to benefit the poorest people in low- and middle-income countries, using Official Development Assistance funding.

About ReCor Medical, Inc.

ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System's intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. For additional information visit http://www.recormedical.com.

Queen Mary University of London

Related Blood Pressure Articles:

Arm cuff blood pressure measurements may fall short for predicting heart disease risk in some people with resistant high blood pressure
A measurement of central blood pressure in people with difficult-to-treat high blood pressure could help reduce risk of heart disease better than traditional arm cuff readings for some patients, according to preliminary research presented at the American Heart Association's Hypertension 2019 Scientific Sessions.
Heating pads may lower blood pressure in people with high blood pressure when lying down
In people with supine hypertension due to autonomic failure, a condition that increases blood pressure when lying down, overnight heat therapy significantly decreased systolic blood pressure compared to a placebo.
The Lancet Neurology: High blood pressure and rising blood pressure between ages 36-53 are associated with smaller brain volume and white matter lesions in later years
A study of the world's oldest, continuously-studied birth cohort tracked blood pressure from early adulthood through to late life and explored its influence on brain pathologies detected using brain scanning in their early 70s.
Blood pressure control is beneficial, is it not?
Until recently, physicians had generally assumed that older adults benefit from keeping their blood pressure below 140/90 mmHg.
The 'blue' in blueberries can help lower blood pressure
A new study published in the Journal of Gerontology Series A has found that eating 200g of blueberries every day for a month can lead to an improvement in blood vessel function and a decrease in systolic blood pressure in healthy people.
How to classify high blood pressure in pregnancy?
The American Heart Association (AHA) and the American College of Cardiology (ACC) changed their guidance to lower the threshold criteria for hypertension in adults.
Discovery could advance blood pressure treatments
A team of Vanderbilt University Medical Center researchers, working with the US Department of Veteran's Affairs (VA), has discovered genetic associations with blood pressure that could guide future treatments for patients with hypertension.
Blue light can reduce blood pressure
Exposure to blue light decreases blood pressure, reducing the risk of developing cardiovascular disease, a new study from the University of Surrey and Heinrich Heine University Dusseldorf in collaboration with Philips reports.
Poor oral health linked to higher blood pressure, worse blood pressure control
Poor oral health may interfere with blood pressure control in people diagnosed with hypertension.
Largest ever genetic study of blood pressure
The largest ever genetic analysis of over one million people has identified 535 new genes associated with high blood pressure.
More Blood Pressure News and Blood Pressure Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.